AvailABIlity:Europe(1),USA(2),other(3)
Content:7.5mLOverview
TheCD14antigenisahigh-affinityreceptorforthelipopolysaccharide(LPS)andLPS-bindingprotein(LPB)complex.
CD14isstronglyexpressedonmosthumanmonocytesandmacrophages.
TheClini
MACS®CD14ProductLineconsistsofmurineanti-CD14monoclonalantibodiesconjugatedtosuperparamagneticirondextranparticles.
Onevialcontains7.5mLsterile,non-pyrogenicsolution.
TheperformanceoftheCliniMACSCD14ProductLinedependsontheindividualseparationstrategy.Forinformationonrespectivecapacities,refertotheCliniMACSUserManualorcontactyourlocalrepresentative.
PleaseinquireaboutrequiredCliniMACSSystemcomponentsandaccessories.
Disclaimer
TheCliniMACS®Systemcomponents,includingReagents,TubingSets,Instruments,andPBS/EDTABuffer,aredesigned,manufacturedandtestedunderaqualitysystemcertifiedtoISO13485.
IntheEU,theCliniMACSSystemcomponentsareavailableasCE-markedmedicaldevicesfortheirrespectiveintendeduse,unlessotherwisestated.TheCliniMACSReagentsandBiotinConjugatesareintendedforinvitrouseonlyandarenotdesignatedfortherapeuticuseordirectinfusionintopatients.TheCliniMACSReagentsincombinationwiththeCliniMACSSystemareintendedtoseparatehumancells.MiltenyiBiotecasthemanufactureroftheCliniMACSSystemdoesnotgiveanyrecommendationsregardingtheuseofseparatedcellsfortherapeuticpurposesanddoesnotmakeanyclaimsregardingaclinicalbenefit.Forthemanufacturinganduseoftargetcellsinhumansthenationallegislationandregulations-e.g.,fortheEUtheDirective2004/23/EC("humantissuesandcells"),ortheDirective2002/98/EC("humanbloodandbloodcomponents")-mustbefollowed.Thus,anyclinicalapplicationofthetargetcellsisexclusivelywithintheresponsibilityoftheuserofaCliniMACSSystem.
IntheUS,theCliniMACSCD34ReagentSystem,includingtheCliniMACSPlusInstrument,CliniMACSCD34Reagent,CliniMACSTubingSetsTSandLS,andtheCliniMACSPBS/EDTABuffer,isFDAapproved;allotherproductsoftheCliniMACSProductLineareavailableforuseonlyunderanapprovedInvestigationalNewDrug(IND)applicationorInvestigationalDeviceExemption(IDE).
CliniMACSMicroBeadsareforresearchuseonlyandnotforhumantherapeuticordiagnosticuse.Unlessotherwisespecificallyindicated,MiltenyiBiotecproductsandservicesareforresearchonlyandnotfortherapeuticordiagnosticuse.
Details
Applications
TheCliniMACSCD14ProductLinewasdevelopedfortheenrichmentofCD14+cellsfromhumanheterogeneoushematologiccellpopulationsincombinationwiththeCliniMACSSystem.
Theenrichedcellscanbeusedforthesubsequentgenerationofhumanmonocyte-deriveddendriticcells(MoDCs).1
Referencedliterature
DCsgeneratedfrommonocytesaftertheenrichmentofCD14+cellsarewellcharacterizedandhavebeenusedforactivevaccinationinmanyclinicaltrials,mainlyinsolidtumorsandhematologicalmalignancies.2-8
Basedonnewinsightintocellularinteractions,aninterestingtherapeuticoptionmightbetheadmi
NISTrationofMoDCsincombinationwiththemodificationofothercellpopulations,forexample,depletionofregulatoryTcells.Fur
Thermore,thetargetedmanipulationofMoDCs,forexample,byelectroporationwithmRNA,mightbeaverypromisingandinnovativeapproachtoimprovetheefficacyofDCs.
8